Fiche publication
Date publication
juillet 2020
Journal
Materials (Basel, Switzerland)
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BENKIRANE-JESSEL Nadia
,
Dr IDOUX-GILLET Ysia
Tous les auteurs :
Smaida R, Pijnenburg L, Irusta S, Himawan E, Mendoza G, Harmouch E, Idoux-Gillet Y, Kuchler-Bopp S, Benkirane-Jessel N, Hua G
Lien Pubmed
Résumé
The treatment of osteochondral defects remains a challenge. Four scaffolds were produced using Food and Drug Administration (FDA)-approved polymers to investigate their therapeutic potential for the regeneration of the osteochondral unit. Polycaprolactone (PCL) and poly(vinyl-pyrrolidone) (PVP) scaffolds were made by electrohydrodynamic techniques. Hydroxyapatite (HAp) and/or sodium hyaluronate (HA) can be then loaded to PCL nanofibers and/or PVP particles. The purpose of adding hydroxyapatite and sodium hyaluronate into PCL/PVP scaffolds is to increase the regenerative ability for subchondral bone and joint cartilage, respectively. Human bone marrow-derived mesenchymal stem cells (hBM-MSCs) were seeded on these biomaterials. The biocompatibility of these biomaterials in vitro and in vivo, as well as their potential to support MSC differentiation under specific chondrogenic or osteogenic conditions, were evaluated. We show here that hBM-MSCs could proliferate and differentiate both in vitro and in vivo on these biomaterials. In addition, the PCL-HAp could effectively increase the mineralization and induce the differentiation of MSCs into osteoblasts in an osteogenic condition. These results indicate that PCL-HAp biomaterials combined with MSCs could be a beneficial candidate for subchondral bone regeneration.
Mots clés
biomaterial, bone engineering, cartilage, hydroxyapatite, osteochondral defect, polycaprolactone, regeneration, scaffold, sodium hyaluronate, stem cells, subchondral bone
Référence
Materials (Basel). 2020 Jul 10;13(14):
